Fabian Gerlinghaus, Cellares CEO

Up­dat­ed: Cel­lares to pro­duce Ca­balet­ta’s au­toim­mune CAR-T can­di­date 

Cel­lares an­nounced a new proof-of-con­cept part­ner­ship with Ca­balet­ta Bio to man­u­fac­ture the biotech’s au­toim­mune CAR-T cell ther­a­py.

The goal of the pro­gram is to “test the Cel­lares sys­tem us­ing Ca­balet­ta’s process and prod­uct to as­sess the plat­form’s abil­i­ty to man­u­fac­ture CA­BA-201,” Ca­balet­ta’s CD19-CAR T can­di­date, ac­cord­ing to Ca­balet­ta chief busi­ness of­fi­cer Arun Das. The tri­als are eval­u­at­ing mul­ti­ple in­di­ca­tions: sys­temic lu­pus ery­the­mato­sus, myosi­tis, sys­temic scle­ro­sis and gen­er­al­ized myas­the­nia gravis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.